Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

8.00USD
19 Jan 2018
Change (% chg)

$-0.18 (-2.20%)
Prev Close
$8.18
Open
$8.14
Day's High
$8.31
Day's Low
$7.92
Volume
53,139
Avg. Vol
70,151
52-wk High
$27.77
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.  Full Article

Ra Pharmaceuticals posts Q3 loss of $0.68 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million​.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.  Full Article

Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article

Lightstone Ventures LP reports 5.9 pct passive stake in Ra Pharmaceuticals Inc as on Dec 31, 2016
Wednesday, 15 Feb 2017 

Ra Pharmaceuticals Inc :Lightstone Ventures L.P. reports 5.9 percent passive stake in ra pharmaceuticals inc as on December 31, 2016 - SEC filing.  Full Article

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage: